About this trial
End-stage renal disease (ESRD) disrupts erythrocyte deformability due to osmotic imbalances, oxidative stress, and uremic toxins, leading to impaired microcirculation and oxygen transport. Dysregulation of ion channels, particularly the Gardos channel, exacerbates dehydration and eryptosis, further compromising vascular integrity. Given the critical role of erythrocyte flexibility in oxygen delivery, this study investigates its relationship with aerobic capacity in ESRD patients, highlighting potential mechanisms of microvascular dysfunction
Eligibility criteria
Qualifiers
Receiving hemodialysis and medication at least for 6 weeks
Kt/V score > 1.2
Disqualifiers
Under 20 years-old
Hyperkalemia occurs within 3 month
Having orthopedic or muscular diseases
Other concerned medical, psychological or physiological diseases
Trial design
Treatments tested in this trial
- Blood collection
- Cardiopulmonary exercise testing (CPET)